98 related articles for article (PubMed ID: 8867484)
1. Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease.
Gryglewski RJ; Grodzińska L; Kostka-Trabka E; Korbut R; Bieroón K; Goszcz A; Sławiński M
Wien Klin Wochenschr; 1996; 108(4):111-6. PubMed ID: 8867484
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study.
Grodzińska L; Starzyk D; Bieroń K; Goszcz A; Korbut R
Basic Clin Pharmacol Toxicol; 2005 Jun; 96(6):413-9. PubMed ID: 15910404
[TBL] [Abstract][Full Text] [Related]
3. L-arginine--substrate for no synthesis--its beneficial effects in therapy of patients with peripheral arterial disease: comparison with placebo-preliminary results.
Slawinski M; Grodzinska L; Kostka-Trabka E; Bieron K; Goszcz A; Gryglewski RJ
Acta Physiol Hung; 1996; 84(4):457-8. PubMed ID: 9328630
[TBL] [Abstract][Full Text] [Related]
4. [Misoprostol--oral prostanoid--the first clinical trial for use in patients with peripheral vascular disease].
Goszcz A; Grodzińska L; Kostka-Trabka E; Bieroń K; Sławiński M; Jachym R; Ochmański W
Przegl Lek; 1997; 54(7-8):505-9. PubMed ID: 9480458
[TBL] [Abstract][Full Text] [Related]
5. Dobutamine effect on ankle-brachial pressure index in patients with peripheral arterial occlusive disease. New noninvasive test for evaluation of peripheral circulation?
Wysokinski WE; Spittell PC; Pellikka PA; Miller WL; Seward JB
Int Angiol; 1998 Sep; 17(3):201-7. PubMed ID: 9821035
[TBL] [Abstract][Full Text] [Related]
6. Some haemorheological factors and transcutaneous PO2 in patients with a peripheral arterial occlusive disease after treatment with naftidrofuryl.
Krupiński K; Bielawiec M; Szpak A; Płonowski A
Mater Med Pol; 1994; 26(1):17-20. PubMed ID: 7857406
[TBL] [Abstract][Full Text] [Related]
7. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
Allegra C; Antignani PL; Schachter I; Koverech A; Messano M; Virmani A
Ann Vasc Surg; 2008; 22(4):552-8. PubMed ID: 18502605
[TBL] [Abstract][Full Text] [Related]
8. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
Maksimović ZV
Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398
[TBL] [Abstract][Full Text] [Related]
9. Effects of a nitric oxide synthase inhibitor on pressor response to angiotensin II in conscious rats.
Maeda T; Yoshimura T; Ohshige A; Koyama H; Ito M; Okamura H
Artery; 1998; 23(1):1-9. PubMed ID: 10846613
[TBL] [Abstract][Full Text] [Related]
10. The influence of two different doses of L-arginine oral supplementation on nitric oxide (NO) concentration and total antioxidant status (TAS) in atherosclerotic patients.
Jabłecka A; Checiński P; Krauss H; Micker M; Ast J
Med Sci Monit; 2004 Jan; 10(1):CR29-32. PubMed ID: 14704633
[TBL] [Abstract][Full Text] [Related]
11. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease.
Gianetti J; De Caterina M; De Cristofaro T; Ungaro B; Guercio RD; De Caterina R
Am Heart J; 2001 Oct; 142(4):733-9. PubMed ID: 11579367
[TBL] [Abstract][Full Text] [Related]
12. Role of endogenous nitric oxide in circadian blood pressure regulation in healthy humans and in patients with hypertension or atherosclerosis.
Bode-Böger SM; Böger RH; Kielstein JT; Löffler M; Schäffer J; Frölich JC
J Investig Med; 2000 Mar; 48(2):125-32. PubMed ID: 10736972
[TBL] [Abstract][Full Text] [Related]
13. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of endogenous L-arginine analogues on nitric oxide synthesis in platelets: role in platelet hyperaggregability in hypertension.
de Meirelles LR; Mendes-Ribeiro AC; Santoro MM; Mendes MA; da Silva MN; Mann GE; Brunini TM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1267-71. PubMed ID: 17973865
[TBL] [Abstract][Full Text] [Related]
15. Prostacyclin and molsidomine synergise in their fibrinolytic and anti-platelet actions in patients with peripheral arterial disease.
Bieroń K; Grodzińska L; Kostka-Trabka E; Gryglewski RJ
Wien Klin Wochenschr; 1993; 105(1):7-11. PubMed ID: 8438599
[TBL] [Abstract][Full Text] [Related]
16. Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?
Schlaich MP; Jacobi J; John S; Delles C; Fleischmann I; Schmieder RE
Clin Sci (Lond); 2000 Oct; 99(4):293-302. PubMed ID: 10995594
[TBL] [Abstract][Full Text] [Related]
17. Statin potentiates human platelet eNOS activity without enhancing eNOS mRNA and protein levels.
Yemisci M; Ay H; Kocaefe C; Qui J; Topalkara K; Ozgüç M; Kirazli S; Ozcebe O; Moskowitz MA; Dalkara T
Cerebrovasc Dis; 2008; 26(2):190-8. PubMed ID: 18628618
[TBL] [Abstract][Full Text] [Related]
18. Treadmill exercise-induced release of endothelin-1 in patients with peripheral arterial occlusive disease at Fontaine stage IIb.
Mangiafico RA; Malatino LS; Spada RS; Santonocito M; Messina R; Dell'Arte S; Attinà T
Int Angiol; 2000 Mar; 19(1):14-7. PubMed ID: 10853680
[TBL] [Abstract][Full Text] [Related]
19. Effects of early enteral arginine supplementation on resuscitation of severe burn patients.
Yan H; Peng X; Huang Y; Zhao M; Li F; Wang P
Burns; 2007 Mar; 33(2):179-84. PubMed ID: 17125930
[TBL] [Abstract][Full Text] [Related]
20. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF.
Tilton RG; Chang KC; LeJeune WS; Stephan CC; Brock TA; Williamson JR
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):689-96. PubMed ID: 10067972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
